Description
DK
Dr. Daria Kwaśniewska
ESMO Certified Consultant Medical Oncologist
Reviewed June 2026
⚠ Prescription required. For informational purposes only. Meds For Cancer is a Named Patient Program facilitator — not a retail pharmacy. A valid oncologist prescription is mandatory before any order is processed.
Is Ibrucent 140 mg right for your situation?
Review these criteria with your oncologist before enquiring✔ You may be a candidate if
- ✓Diagnosed with CLL, SLL, MCL, or Waldenström’s macroglobulinemia
- ✓Your oncologist has recommended a daily oral BTK inhibitor
- ✓Seeking a WHO-GMP generic alternative to Imbruvica® made by Incepta
- ✓Hold a valid oncologist prescription
✖ May NOT be suitable if
- ✗On strong blood thinners (warfarin) or have a severe bleeding disorder
- ✗Uncontrolled atrial fibrillation or severe liver impairment
- ✗Pregnant, planning pregnancy, or breastfeeding
- ✗Regular grapefruit or Seville orange consumer (CYP3A4 interaction)
Check Availability & Pricing
Prescription required · Named Patient Program · Worldwide shipping
🛡 WHO-GMP Certified · Prescription verified · Express dispatch
What is Ibrucent 140 mg?
Ibrucent 140 mg is a generic formulation of Ibrutinib — a Bruton’s Tyrosine Kinase (BTK) inhibitor — manufactured by Incepta Pharmaceuticals Ltd., one of Bangladesh’s largest and most established pharmaceutical manufacturers. Each capsule contains 140 mg of ibrutinib, the same active molecule found in Imbruvica® (Pfizer/Janssen), and is dispensed under the Named Patient Program for patients requiring a quality-assured, affordable alternative.
| Generic name | Ibrutinib |
| Reference brand | Imbruvica® (Pfizer / Janssen) |
| Manufacturer | Incepta Pharmaceuticals Ltd. |
| Standard | WHO-GMP Certified |
| Drug class | BTK Inhibitor (Kinase inhibitor) |
| Dosage form | Hard capsule — 140 mg |
| Pack sizes | 12’s strip / 90’s pot |
| Route | Oral · once daily |
| Prescription | Required — oncologist only |
How Ibrutinib Works
In blood cancers like CLL and MCL, the BTK (Bruton’s Tyrosine Kinase) signalling pathway is chronically overactive — cancer cells exploit it to survive, proliferate, and evade the immune system. Ibrutinib permanently and covalently binds to BTK at the Cys481 residue, blocking this pathway completely.
Unlike traditional chemotherapy which destroys healthy and cancerous cells alike, ibrutinib acts as a precision-targeted agent — selectively starving cancer cells of their survival signal while leaving healthy immune cells comparatively intact. NCCN guidelines list ibrutinib as a Category 1 recommendation for first-line and relapsed/refractory CLL/SLL. View NCCN CLL Guidelines →
What to Expect: First 30 Days
Every patient’s response is individual. The pattern below reflects common early experiences — your care team will guide you through each stage.
- Week 1: Mild fatigue, nausea, or easy bruising are common. A temporary rise in lymphocyte count (lymphocytosis) is expected and normal — it signals the drug is displacing cancer cells from lymph nodes into the bloodstream where they are cleared. This is not disease progression.
- Weeks 2–3: Mild diarrhoea, joint aches, or a faint skin rash may develop. Scheduled blood tests will monitor your counts, liver enzymes, and kidney function — attend all appointments.
- Week 4: Most patients report stabilising energy levels. Oncologists frequently observe measurable shrinkage of enlarged lymph nodes or spleen on imaging by the end of the first month.
Side Effects
Side effects vary by individual and tend to be most pronounced in the first few weeks. Most are manageable — always report new or worsening symptoms to your oncologist promptly.
Common · Usually Manageable
- Diarrhoea or loose stools
- Fatigue and weakness
- Muscle or joint pain
- Minor bruising or petechiae
- Mild skin rash or nail changes
- Headache · elevated blood pressure
- Temporary lymphocyte count rise
Serious · Report Immediately
- Major or unexplained bleeding
- Atrial fibrillation or palpitations
- Severe or opportunistic infections
- Tumour lysis syndrome (early treatment)
- Significantly elevated liver enzymes
⚠ Call your doctor or go to A&E immediately if you experience:
- Blood in stool, urine, vomit, or coughing up blood
- Racing, fluttering, or sustained irregular heartbeat
- High fever, shaking chills, or sudden breathing difficulty
How to Take Ibrucent 140 mg
Standard CLL/SLL dose: 3 capsules (420 mg) once daily. For MCL and Waldenström’s the dose may differ — always follow your oncologist’s exact prescription.
- 1Once daily — take at the same time each day. Consistency of timing improves steady-state drug levels.
- 2Swallow capsules whole with a full glass of water. Never open, crush, chew, or dissolve them — this disrupts absorption and is clinically unsafe.
- 3With or without food — avoid grapefruit, Seville oranges, and St John’s Wort entirely throughout treatment (CYP3A4 interactions alter drug levels significantly).
- 4Never stop without medical instruction — abrupt discontinuation causes rapid disease rebound, often within days.
- 5Storage: below 25°C in original packaging, away from moisture, direct sunlight, and out of reach of children.
Caregiver Guidance
- ♥Monitor blood pressure and pulse daily — ibrutinib can cause hypertension or atrial fibrillation, particularly in the first three months. Keep a written log to share at clinic visits.
- ♥Watch for bleeding signs: unusual bruising, nosebleeds, prolonged bleeding from small cuts, or red spots on skin. Report these immediately, especially if the patient is on any antiplatelet or anticoagulant medication.
- ♥Set a daily medication alarm, check the diet for grapefruit products, and bring a full medication list to every pharmacy or clinic visit to screen for interactions.
If the Medicine Stops Working
With prolonged ibrutinib therapy, some CLL clones can acquire the BTK C481S point mutation, which prevents covalent binding of ibrutinib to BTK and restores cancer-cell survival signalling. Less commonly, mutations in PLCg2 downstream of BTK can bypass the block entirely. If clinical or laboratory progression occurs, your oncologist will typically perform genetic/mutation profiling and may transition to a non-covalent, next-generation BTK inhibitor such as zanubrutinib or pirtobrutinib, or to a venetoclax-based combination. Regular blood counts and periodic imaging are essential for early detection of emerging resistance.
Frequently Asked Questions
How is Ibrucent different from Ibruxen or Ibrutix?
All three contain the same active molecule — ibrutinib 140 mg — and target the same BTK pathway. The difference is the manufacturer: Ibrucent is made by Incepta Pharmaceuticals Ltd., Ibruxen by Everest Pharmaceuticals, and Ibrutix by a different facility. All are WHO-GMP certified generics dispensed under the Named Patient Program. Your oncologist or our team can advise on availability and pricing for your region.
Ibrucent contains the identical active pharmaceutical ingredient — ibrutinib — at the same 140 mg dose strength. It is manufactured under WHO-GMP conditions that ensure consistent potency, purity, and dissolution. While brand-specific head-to-head bioequivalence data for Ibrucent is not publicly filed, the standards applied are consistent with international generic pharmaceutical practice. Clinical decisions should always involve your treating oncologist.
Ibrutinib acts on cancer cells immediately at the molecular level. Most patients notice physical reduction in swollen lymph nodes or improved blood counts within 4–8 weeks. The temporary lymphocyte spike in week one is not a sign of failure — it is a pharmacological effect of the drug working.
Ibrutinib has significant interactions with blood thinners (warfarin, aspirin, clopidogrel), antifungals (ketoconazole, fluconazole), certain antibiotics (clarithromycin), and some heart medications. Always provide your full medication list — including supplements and herbal products — to both your oncologist and pharmacist before starting.
Contact us via WhatsApp (+880 130 449 8958) or email (info@medsforcancer.com) with your oncologist’s prescription. Our team will verify the prescription, confirm availability and pricing for your country, and arrange secure international shipping under the Named Patient Program framework. We do not dispense without a valid prescription.
Significant alopecia (hair loss) is not a recognised side effect of ibrutinib — this is one of the notable advantages over traditional IV chemotherapy. Some patients report mild, temporary hair thinning, but major hair loss is uncommon. Discuss any hair changes with your oncologist to rule out other causes.
🛡 Named Patient Program — Regulatory Framework
Meds For Cancer operates as a Named Patient Program (NPP) facilitator. Under this framework, WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid oncologist prescription, in countries where the branded product is unavailable or unaffordable.
This service does not constitute retail pharmacy dispensing. A prescription review is mandatory before any order is processed.
Clinical References
- Byrd JC, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukaemia. NEJM 2014;371:213–223.
- Woyach JA, et al. Resistance mechanisms for the BTK inhibitor ibrutinib. NEJM 2014;370:2286–2294.
- NCCN Clinical Practice Guidelines in Oncology: CLL/SLL. V2.2026.
- Wang ML, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. NEJM 2013;369:507–516.
